Clinical Trial Update: Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML [Phase 1, Phase 2]

View source ↗

Summary

A combined Phase 1/Phase 2 study evaluating vorinostat, azacitidine, and gemtuzumab ozogamicin in older adults with relapsed or refractory acute myeloid leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-02-06